Mescaline, one of the first classical psychedelics, is beginning to attract the interest of psychedelic researchers conducting clinical trials.
The anesthetic gas could provide the same rapid relief of severe depression as ketamine, but with fewer side effects.
The public conversation around drugs is shifting, as harm reduction advocates point to a growing body of evidence that most harm and fatalities derive from preventable circumstances.
New research on mice suggests that the “trip is not necessary for the acute antidepressant effect.”
Therapists participating in Compass Pathways clinical trials receive instruction in a proprietary training methodology and model of psychological support.
The first academic post-graduate certification program in the U.S. focused on psychedelic therapy now has a second training center outside San Francisco.
Small doses of psilocybin are shown in a study to provide effective relief from migraine headaches.
Researchers found that psilocybin-assisted psychotherapy for advanced cancer patients may be an effective alternative to existing antidepressant medications to prevent suicide.
His desperate search for sobriety led him to Mexico for treatment using 5-MeO-DMT, reflecting a growing interest in psychedelic-assisted therapies for addiction.